Cargando…

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I

Mucopolysaccharidosis type I (MPS I) is a progressive disorder caused by deficiency of α-L-iduronidase (IDUA), which leads to storage of heparan and dermatan sulphate. It is suggested that early enzyme replacement therapy (ERT) leads to better outcomes, although many patients are diagnosed late and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasqualim, Gabriela, Baldo, Guilherme, de Carvalho, Talita Giacomet, Tavares, Angela Maria Vicente, Giugliani, Roberto, Matte, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315431/ https://www.ncbi.nlm.nih.gov/pubmed/25646802 http://dx.doi.org/10.1371/journal.pone.0117271

Ejemplares similares

Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases
por: Poletto, Edina, et al.
Publicado: (2019)

Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
por: Fraga, Michelle, et al.
Publicado: (2017)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes
por: Borges, Pâmella, et al.
Publicado: (2020)

Comment on “report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I”
por: Poletto, Edina, et al.
Publicado: (2018)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Which Is the Best In Silico Program for the Missense Variations in IDUA Gene? A Comparison of 33 Programs Plus a Conservation Score and Evaluation of 586 Missense Variants
por: Borges, Pâmella, et al.
Publicado: (2021)

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I
por: Le, Steven Q., et al.
Publicado: (2017)

Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): a case report
por: Andrade, Isadora, et al.
Publicado: (2022)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzyme Replacement Therapy
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2022)

Drug Repositioning Applied to Cardiovascular Disease in Mucopolysaccharidosis
por: Villalba Silva, Gerda Cristal, et al.
Publicado: (2022)

Phenotype-oriented NGS panels for mucopolysaccharidoses: Validation and potential use in the diagnostic flowchart
por: Brusius-Facchin, Ana Carolina, et al.
Publicado: (2019)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model
por: Sawamoto, Kazuki, et al.
Publicado: (2019)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Crossing the gates of Babylon: Brain-penetrating enzyme replacement for lysosomal disorders
por: Baldo, Guilherme
Publicado: (2023)

Cathepsin B-associated Activation of Amyloidogenic Pathway in Murine Mucopolysaccharidosis Type I Brain Cortex
por: Viana, Gustavo Monteiro, et al.
Publicado: (2020)

ELAG – 10 Successful Years
por: Giugliani, Roberto, et al.
Publicado: (2014)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs
por: Gawri, Rahul, et al.
Publicado: (2022)

Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders
por: Málaga, Diana Rojas, et al.
Publicado: (2019)

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
por: Harmatz, Paul, et al.
Publicado: (2010)

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
por: Hendriksz, Christian J., et al.
Publicado: (2014)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017)

Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI
por: Eliyahu, Efrat, et al.
Publicado: (2011)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
por: Cho, Sung Yoon, et al.
Publicado: (2014)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
por: Yamanishi, Ryutaro, et al.
Publicado: (2019)

Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
por: Politei, Juan, et al.
Publicado: (2021)

Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
por: Lee, Seung Hoon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vr0phl3kp7r834nboitmnis9vb